Analysts Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target at $11.50

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have been given an average rating of “Moderate Buy” by the seven brokerages that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $11.50.

A number of equities research analysts have recently commented on the company. Piper Sandler lowered their price objective on Karyopharm Therapeutics to $7.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Robert W. Baird downgraded shares of Karyopharm Therapeutics from an “outperform” rating to a “neutral” rating and set a $3.00 target price on the stock. in a research note on Friday, July 31st. Weiss Ratings lowered Karyopharm Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 28th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $16.00 price objective on shares of Karyopharm Therapeutics in a report on Tuesday, July 21st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Karyopharm Therapeutics in a research report on Tuesday, June 9th.

Hedge Funds Weigh In On Karyopharm Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Baird Financial Group Inc. acquired a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at about $45,000. XTX Topco Ltd bought a new position in Karyopharm Therapeutics in the 2nd quarter worth approximately $56,000. Hsbc Holdings PLC acquired a new position in shares of Karyopharm Therapeutics during the first quarter valued at $66,000. Corient Private Wealth LLC acquired a new position in Karyopharm Therapeutics during the 4th quarter valued at about $74,000. Finally, Tudor Investment Corp ET AL bought a new stake in Karyopharm Therapeutics during the fourth quarter worth approximately $95,000. Institutional investors and hedge funds own 66.44% of the company’s stock.

Karyopharm Therapeutics Price Performance

Shares of NASDAQ KPTI opened at $2.03 on Thursday. The firm’s 50-day moving average is $7.75 and its two-hundred day moving average is $7.93. The company has a market capitalization of $46.00 million, a PE ratio of -0.13 and a beta of 0.89. Karyopharm Therapeutics has a 12-month low of $1.80 and a 12-month high of $10.99.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Thursday, May 14th. The company reported ($1.24) earnings per share for the quarter, topping the consensus estimate of ($1.45) by $0.21. The company had revenue of $35.07 million for the quarter, compared to analysts’ expectations of $31.40 million. On average, analysts forecast that Karyopharm Therapeutics will post -4.29 EPS for the current fiscal year.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.